CurrentCignaPolicy N/A

Ophthalmology - Dry Eye Disease - Eysuvis Prior Authorization Policy

Prior authorization policy for prescription benefit coverage of Eysuvis for treatment of dry eye disease for members of Cigna-administered health benefit plans. Defines FDA-approved indication coverage, approval duration, and non-covered uses.

Policy Summary

PayerCigna

PolicyOphthalmology - Dry Eye Disease - Eysuvis Prior Authorization Policy

Policy CodePolicy N/A

Change TypeClarified (annual revisionno criteria changes)

Effective Date

Next Review Date

Key ActionPrior authorization is required; document a trial of artificial tears and note approvals are provided for 1 month (30 days).

SourceLink

POLICY UPDATE CHANGES

Annual revision completed with no criteria changes as of 12/11/2024.

1Covered Indications

1 monthInitial Approval Duration

All other usesNot Covered / Experimental

Coverage Summary

Prior authorization policy for prescription benefit coverage of Eysuvis for treatment of dry eye disease for members of Cigna-administered health benefit plans. Coverage stance: covered_with_criteria.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions & Requirements

Prior Authorization

Prior authorization required

Prior authorization is recommended/required for prescription benefit coverage of Eysuvis; approvals provided for specified duration (1 month = 30 days).

Approval duration: 1 month (30 days)

Documentation Required

Document trial of artificial tears

Provider must document that the patient has tried artificial tears prior to approval.

Denial Risk

Denial for non-FDA uses

Claims for any use other than short-term treatment of dry eye disease may be considered experimental/investigational and denied.

Clinical Evidence & References

Evidence includes: FDA Prescribing Information: Eysuvis ophthalmic suspension; Alcon; November 2023 and the AAO Dry Eye Syndrome Preferred Practice Pattern, Ophthalmology 2024;131(4):P1-P49.

Clinical monitoring is recommended for adverse effects of ophthalmic corticosteroids, specifically increased intraocular pressure and cataract formation.

Background & Definitions

Eysuvis is an ophthalmic corticosteroid indicated for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease.

Ophthalmic corticosteroids can reduce ocular irritation symptoms; patients should be monitored for adverse effects such as increased intraocular pressure and cataract formation.

Definitions

TermShort-term

DefinitionPolicy references FDA indication as short-term (up to 2 weeks) treatment; approval duration by policy is 1 month (30 days).

Source statementEysuvis is indicated for short-term (up to 2 weeks) treatment of signs and symptoms of dry eye disease; approvals are provided for 1 month (1 month = 30 days).